Abstracts 54-OR and 55-OR
Secondary data at 52 weeks demonstrated statistically significant blood sugar reductions and statistically significant reduction of body weight vs both Jardiance(R) and Victoza(R)
Findings presented today from two phase 3a clinical trials evaluated oral semaglutide 14 mg vs Jardiance(R) (empagliflozin 25 mg) in PIONEER 2 and oral semaglutide 14 mg versus Victoza(R) (liraglutide 1.8 mg) in PIONEER 4 over 52 weeks in adults with type 2 diabetes. Data from both trials were presented at the American Diabetes Association (ADA) 79th Scientific Sessions. Oral semaglutide is an investigational once-daily glucagon-like peptide-1 (GLP-1) analogue in a pill.
In PIONEER 2, oral semaglutide 14 mg demonstrated a superior HbA1c reduction of 1.3% compared to a 0.9% reduction with empagliflozin 25 mg for the primary endpoint at 26 weeks (p
